Table II.
Univariate analysis of the prognostic characteristics for primary gastrointestinal diffuse large B-cell lymphoma.
| Characteristic | OS, HR (95% CI) | P-value | PFS, HR (95% CI) | P-value |
|---|---|---|---|---|
| miR-150 expression (Low vs. high) | 1.761 (1.101–2.814) | 0.018a | 1.873 (1.170–2.998) | 0.009a |
| Treatment (CHOP vs. R-CHOP) | 1.972 (1.251–3.108) | 0.003a | 2.704 (1.314–3.274) | 0.002a |
| IPI score (0–2 vs. 3–5) | 1.984 (1.236–3.185) | 0.005a | 2.054 (1.279–3.300) | 0.003a |
| ECOG (0–1 vs. 2–4) | 1.298 (0.822–2.049) | 0.263 | 1.358 (0.860–2.143) | 0.189 |
| Lugano staging status (I–II vs. IIE-IV) | 1.165 (0.737–1.842) | 0.513 | 1.230 (0.778–1.944) | 0.376 |
a
P<0.05. OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; miR, microRNA; IPI, International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisoneor; R-CHOP, CHOP-like regimen with rituximab.